Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Reuters NewMedia, Inc. - Friday July 25 9:18 AM EDT
The company said that in the Phase II trial, three of the nine subjects tested experienced decreases in platelet counts that required dose interruption.
In addition, the company said, a review of the data showed inconsistent responses to the treatment. Hybridon said it was proceeding with the development of GEM92, an advanced chemistry compound for the treatment of HIV. The drug is scheduled to enter clinical trials in October.
The company also said that it has withdrawn its shelf registration statement filed with the Securities and Exchange Commission relating to a primary offering of up to 5,000,000 shares of common stock.
The company further said that it plans to cut back its expenditure rate on a phased basis over the rest of 1997 through cost savings associated with stopping the development of GEM91 and by reducing or suspending selected programs.
It said it is in preliminary discussions with potential collaborative partners with respect to certain of its research and development programs.
970725
RE970717
Copyright © 1997 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .